Indivior parts with $30m in Suboxone dispute

The pharmaceutical company agreed to pay millions to resolve a multi-district antitrust suit brought by more than 40 US state attorneys | Company sued over alleged actions aimed at preserving the monopoly of anti-addiction drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Indivior avoids multi-state antitrust trial with $100m payout

6 June 2023 Case involved the alleged monopolisation of an opioid addiction treatment | More than 40 attorneys general had filed complaints against the pharma company.

Big Pharma

Fed Circ says Indivior patent was anticipated

30 November 2021 The US Court of Appeals for the Federal Circuit has affirmed a US Patent Trial and Appeal Board decision that held that claims of a patent for dissolvable films containing therapeutic agents were anticipated.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Indivior parts with $30m in Suboxone dispute

More on this story

Editor's picks

Editor's picks

More features